Thrombosis |
From the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (M.C.M., C.E.H.), Laboratory for Clinical and Experimental Immunology, Amsterdam; the Center for Hemostasis, Thrombosis, Atherosclerosis, and Inflammation Research (M.C.M., M.E.W., N.S., J.J.P.K., H.t.C.), Academic Medical Center, University of Amsterdam, Amsterdam; and the Department of Internal Medicine (H.t.C.), Slotervaart Hospital, Amsterdam, the Netherlands.
Correspondence to M.C. Minnema, MD, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Laboratory for Clinical and Experimental Immunology, Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands.
AbstractIn vitro,
triglyceride-rich lipoproteins may act as a surface to
initiate the contact system of coagulation. Therefore, we studied the
activation of factor XII (FXII), prekallikrein, and FXI
and the generation of thrombin in 52
hypertriglyceridemic patients before and
after 12 weeks of triglyceride-lowering treatment with
gemfibrozil or n-3 polyunsaturated fatty acids. Thrombin
generation was assessed by measuring the levels of prothrombin fragment
F1+2 and thrombin-antithrombin (TAT) complexes. Contact activation was
assessed by measuring FXIIa, kallikrein, and FXIa in complex with their
major inhibitor, C1 inhibitor, and FXIa was
also determined as part of a complex with
1-antitrypsin.
Triglyceride and cholesterol levels decreased
equally in both treatment groups. In the gemfibrozil group, there was a
significant decrease in F1+2, while TAT complexes did not change.
FXIIa- and kallikrein-C1 inhibitor complexes were elevated
in 13% and 9% of the patients before treatment, respectively, and no
changes were observed on triglyceride-lowering therapy.
Also, no significant changes in regard to FXIaC1
inhibitor and FXIa
1-antitrypsin complexes
were seen. FXIa
1-antitrypsin complexes were
present in 70% of the patients before therapy and were positively
correlated with the level of TAT complexes. In conclusion, we did not
detect an effect on activation markers of the contact coagulation
system in hypertriglyceridemic patients
after triglyceride-lowering therapy. Therefore, contact
activation is not likely to contribute to the hypercoagulability seen
in these patients.
Key Words: hypertriglyceridemia contact system blood coagulation
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |